XGN · Exagen Inc.
Market Cap
$203.74M
Shares
24.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.41
Open$7.87
Day$7.87–8.42
52W close$2.65–11.96
Avg vol 30d288K
Short int864K · 3.6% float · 2.6d
Short vol47%
Last earningsAug 4, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 6 wks
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$71.12M
Trailing 12 months
Net income (TTM)
−$18.92M
Trailing 12 months
Revenue growth YoY
+15.9%
Year over year
Operating margin
-18.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.75M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.6%
Year over year · more shares
Price change (1Y)
-12.8%
Trailing year
Short interest
3.6%
Latest settlement · 2.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+76%
above
Price vs 50-day avg
+33%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+214%
trailing
YTD return
+38%
this year
Relative strength
+194%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-7% holders QoQ · +8 funds added
Insider flow
Distributing
Net -$148.8K over 90 days · 100% sells
Short interest
Falling
3.57% of float · ▼ -8.1% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
58%
contracting
EPS growth
−12%
Y/Y
Free cash flow
$-14.3M
Balance sheet
$9.3M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Full-year 2026 revenue
· full-year 2026
Initiated
$72M – $75M
prior FY $66.58M
midpoint +10.4% Y/Y
Prior guidance
period ended
· from the 8-K filed Aug 5, 2024
Full-year 2024 revenue
· full year 2024
at least $57M
Guided vs delivered
· last 2 settled
Full-year 2024 revenue
full year 2024
guided at least $57M
$55.64M
Miss −2.4%
Total revenue
first quarter 2024
guided $13M – $13.5M
$14.42M
Beat +8.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+76%
Bullish
Price vs 50-day avg
+33%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-7% holders QoQ · +8 funds added
Insider flow
Distributing
Net -$148.8K over 90 days · 100% sells
Short interest
Falling
3.57% of float · ▼ -8.1% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $8 · 62%
Range high $12
vs 200-day avg +76%
vs 50-day avg +33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XGN
this stock
Exagen Inc.
|
$203.74M | +38.3% | +19.7% | — | 3.6% |
|
TMO
Thermo Fisher Scientific Inc.
|
$240.87B | +12.4% | +14.5% | 35.0 | 1.5% |
|
DHR
Danaher Corp /De/
|
$147.37B | -7.5% | +8.5% | 37.2 | 1.4% |
|
NTRA
Natera, Inc.
|
$53.25B | +61.2% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$44.71B | +18.2% | +41.6% | 33.3 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XGN | +19.6% | +8.1% | +213.8% | +14.6% | +38.3% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +20.0% | +8.2% | +193.7% | +15.3% | +26.6% |